Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention

Xiao-juan Ma; Hui-jun Yin; Ke-ji Chen

doi:10.1007/s11655-009-0236-3

Your Location：

Home >

Browse articles >

Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention

Updated：2021-08-27

- Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention
- Chinese Journal of Integrative Medicine Vol. 15, Issue 3, Pages: 236-240(2009)
- Affiliations：
  
  Department of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation Major Research Plan (No. 90409021)
- DOI：10.1007/s11655-009-0236-3
  CLC：
- Published：2009，
  
  Published Online：2 July 2009，
Scan for full text
Ma, Xj., Yin, Hj. & Chen, Kj. Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention., Chin. J. Integr. Med. 15, 236–240 (2009). https://doi.org/10.1007/s11655-009-0236-3

Xiao-juan Ma, Hui-jun Yin, Ke-ji Chen. Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. [J]. Chinese Journal of Integrative Medicine 15(3):236-240(2009)
Ma, Xj., Yin, Hj. & Chen, Kj. Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention., Chin. J. Integr. Med. 15, 236–240 (2009). https://doi.org/10.1007/s11655-009-0236-3 DOI：

Xiao-juan Ma, Hui-jun Yin, Ke-ji Chen. Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. [J]. Chinese Journal of Integrative Medicine 15(3):236-240(2009) DOI： 10.1007/s11655-009-0236-3.

摘要

Acute myocardial infarction (AMI) is still the leading factor causing crippling and death in cardiovascular disease. Percutaneous coronary intervention (PCI) can significantly reduce inpatient mortality and incidence of complication. But owing to the existence of restenosis

in-stent thrombosis

etc.

recurrent post-PCI cardiovascular events and high repeatability of hospitalization

as well as its crippling rate and mortality

remain a serious threat to the society and the patients’ family. Therefore

the appraisal and intervention in post-PCI associated risk factors has presently become one of the foci in clinical research. To improve the near- and long-term prognosis and quality of life in post-PCI AMI patients

further improvement of the evaluation system in risk factors and prognosis is necessary in order to provide a theoretical basis for early application of intervention in high-risk patients in clinical practice. This thesis mainly dissertates some explicit and valuable factors for clinical prognosis evaluation in recent studies

involving C-reactive protein (CRP)

tumor necrosis factor-α (TNF-α)

brain natriuretic peptide (BNP)

atrial natriuretic peptide (ANP)

Chinese medicine (TCM) syndrome

their correlation with clinical state and course of AMI

and their importance in clinical prognosis.

Abstract

in-stent thrombosis

etc.

recurrent post-PCI cardiovascular events and high repeatability of hospitalization

as well as its crippling rate and mortality

remain a serious threat to the society and the patients’ family. Therefore

involving C-reactive protein (CRP)

tumor necrosis factor-α (TNF-α)

brain natriuretic peptide (BNP)

atrial natriuretic peptide (ANP)

Chinese medicine (TCM) syndrome

their correlation with clinical state and course of AMI

and their importance in clinical prognosis.

关键词

myocardial infarctionPercutaneous Coronary Interventionprognosis

Keywords

myocardial infarctionPercutaneous Coronary Interventionprognosis

references

Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005;19:1998–2004.

Raja SG, Berg GA. Safety of drug eluting stents: current concerns and controversies. Curr Drug Saf 2007;2: 212–219.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.

Li L, Guo YH, Wang GS, Guo LJ, Zhang FC, Gao W. Value of hypersensitive C-reactive protein for predicting the prognosis of patients after emergent percutaneous coronary intervention. Chin J Minim Invas Surg (Chin) 2006;6: 483–485.

Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of highsensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007;99:31–35.

Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778–784.

Smit JJ, Ottervanger JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC, et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol 2008;101:446–451.

Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffr`e PA. Predictive value of C-reactive protein in patients with unstable angina pectosis undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92–95.

Zhang M, Huang TG, Zhou LJ, Zhang YZ, Zhang WH. Serum CRP, SAA, IL-6 in patients with acute myocardial infarction and effective of PCI on them. South Chin J Cardiol Dis (Chin) 2004;10:412–415.

Chen L, Li JJ. The relativity between tumor necrosis factor-α and chronic congestive heart failure. J Chin Microcirc (Chin) 2004;14: 56–58.

Chen BY, Li XQ, Chen XL. Study in the serum TNF-α, IL-1β and IL-6 patient with congestive heart failure. J Clin Inter, Med (Chin) 2006;23:184–185.

Ke JJ, Wang YL, Li JG, Wu J, Feng XB. Pretreatment effect of adenosine on activation of NF-kappaB and level of TNF-α during myocardial ischemia and reperfusion in rats. Chin J Traumatol (Chin) 2004;7:25–27.

Lv JP, Wang SR, Ma ZC, Wang SQ. Proteomic analysis of the effects of tumor necrosis factor-α on endothelial cells. Chin J Pathophysiol (Chin) 2004; 20: 1121–1125.

Kang YJ. Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect 2001; 109: 27–34.

Lin ZJ, Pan H. The role of IL-10 and TNF-α in acute coronary syndrome. Prev Treat Cardio Cereb Vas Dis (Chin) 2006;6:297–299.

Liu D, Zhao L. Dynamic Change of tumor necrosis factor-α in patients of acute myocardial infarction. Chin J Inter Med (Chin) 2000; 39:499.

Kubica J, Kozinski M, Krzewina-Kowalska A, Zbikowska-Gotz M, Dymek G, Sukiennik A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 2005;16:173–180.

Pan XM, Wu ZG, Huang Z, Ren YS, He SQ, Zhu LX. The influence of elevated TNF-α levels on prognosis after AMI. Chin Heart J (Chin) 2004;16:39–40.

Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964–1970.

Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis heart failure. N Engl J Med 2002; 347:161–167.

Maisel AS. Practical approaches to treating patients with acute decompensated heart failure. J Cardiac Fail 2001; 7: 13–17.

Wu ZD, Wang MH, Yu XD, Huang JF, Ge RT. Effects of percutanious coronary intervention on plasma brain natriuretic peptide level in patients with acute coronary syndrome. Fujian Med J (Chin) 2006;2:101–102.

Yildirir A, Acikel S, Ertan C, Aydinalp A, Ozin B, Muderrisoglu H. Value of peri-procedural B-type natriuretic peptide levels in predicting cardiac events after elective percutaneous coronary intervention. Acta Cardiol 2008;63:47–52.

Liang JQ, Zhou XX, Huang YG, Zhang GX. Effect of primary percutaneous coronary intervention on plasma B-type natriuretic peptide in patients with acute myocardial infarction. J First Milit Med Univ (Chin) 2005;25: 1555–1557.

Li G, Gong YC, Chen S, Ding JD, Feng Y. Effect of urgent percutaneous coronary intervention on brain natriuretic peptide level in patients with acute myocardial infarction. Chin J Cardiol Med (Chin) 2006;11:119–120.

Ahmed W, Zafar S, Alam AY, Ahktar N, Shah MA, Alpert MA. Plasma levels of B-type natriuretic peptide in patients with unstable angina pectoris or acute myocardial infarction: prognostic significance and therapeutic implications. Angiology 2007;58:269–274.

Du TX, Wang ZZ, Wang SK, Luo J. Clinical analysis of the changes of plasma BNP, ET, CRP and ANP levels in patients with acute myocardial infarction. J Radioimmunol (Chin) 2004;17:6–7.

Sun JB, Lu XG, Zhang L, Peng HH. Study and progress of cardionatrin in medical science and sports medicine. Chin J Clin Rehabil (Chin) 2005;9:198–199.

Xiao YY, Jia WJ, Liu ZW, Zu J. Comparison of plasma level of artrial natriuretic factor in patients with acute myocardial infarction before and after treatment. Labeled Immunoassays Clin Med (Chin) 1999; 6:152–154.

Liu XZ, Xu JP, Zhao KQ, Shang SZ, Zhao YT, Zhang QJ, et al. Measurement of the plasma ANP and serum CK-MB in patients with acute myocardial infarction. J Zhengzhou Univ (Sci Med, Chin) 2004;39:633–636.

Zhao HL, Li L, Wang Y. Plasma levels of atrial natriuretic peptide and brain natriuretic peptide in patients with acute myocardial infarction in Killip classes II underwent percutaneous coronary intervention. Chin J Cardiol Med (Chin) 2005;10:109–110.

Peng JJ, Wu Y, Hu DY, Gao XH, Zhang YC, Jia SQ. Serial changes and prognostic significance of atrial natriuretic polypeptide in patients with acute myocardial infarction undergoing emergency coronary intervention. Chin J Med Guide (Chin) 2004;6:340–342.

Li NY, Li YY, Hong CX, Long HS. Exploration on the relationship between pathogenesis for yin-deficiency of acute myocardial infarction and immediate prognosis as well as its mechanism. Chin J Integr Tradit Chin West Med (Chin) 2004;24:400–403.

Yin KC, Luo Y, Zhang BP, Liu T, Zhong SJ, Tang XC, et al. Characteristics of differentiating symptoms and signs and prognosis analysis on 65 cases of acute myocardial infarction. J Pract Tradit Chin Med (Chin) 2001;17:3–4.

Zhang BT, Yan QL, Yan DX, Hu QL. Study on the number of vulnerable vessels, level of coronary artery stenosis, integral of Braunwald clinical grades and their correlation among different traditional Chinese medcine syndromes in patients with acute coronary syndromes. J Emerg Tradit Chin Med (Chin) 2005;14:147–149.

FULL TEXT LINK

More>

Views

382

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The preventive effect of garlicin on a porcine model of myocardial infarction reperfusion no-reflow

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

Summary of 2011 Integrative Medical Doctors Conference

Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention

Related Author

No data

Related Institution

Department of Integrative Cardiology, China-Japan Friendship Hospital

Department of Cardiology, China-Japan Friendship Hospital

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Department of Cardiology, Peking University First Hospital

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰